

Supplementary table S1. Relative changes in antibody levels in early rheumatoid arthritis, and their correlations to changes in disease activity and inflammatory markers. CCP: cyclic citrullinated peptide; CEP-1: citrullinated α -enolase peptide-1; cFib: citrullinated fibrinogen peptide; CRP = C-reactive protein; cVim: citrullinated vimentin peptide; DAS28 = 28-joint disease activity score; ESR = Erythrocyte sedimentation rate; IQR: interquartile range. Statistically significant correlations are shown in bold.

A. Months 0-3; Methotrexate monotherapy

		CCP (n=209)	CEP-1 (n=124)	cVim (n=91)	cFib (n=88)
Change in antibody level					
Median % (IQR)		-28.2 (-3.9 to -44.4)	-30.0 (-12.5 to -47.2)	-28.6 (-8.5 to -38.8)	-28.0 (4.2 to -47.6)
ESR	Rho	0.11	0.21	0.19	0.24
	P-value	0.11	0.017	0.071	0.022
CRP	Rho	0.03	0.07	-0.02	0.22
	P-value	0.65	0.45	0.89	0.041
DAS28	Rho	0.16	0.10	0.17	0.16
	P-value	0.025	0.27	0.11	0.15

B. Months 3-12; Add-on therapy

		CCP (n=115)	CEP-1 (n=58)	cVim (n=41)	cFib (n=46)
Change in antibody level					
Median % (IQR)		-26.1 (13 to -51.2)	-29.1 (0.2 to -48.2)	-23.0 (-2 to -35.5)	-28.0 (4.2 to -47.6)
ESR	Rho	0.13	0.27	0.03	0.37
	P-value	0.19	0.040	0.87	0.012
CRP	Rho	-0.01	0.09	0.07	0.29
	P-value	0.91	0.51	0.67	0.13
DAS28	Rho	0.21	0.18	0.25	0.35
	P-value	0.027	0.17	0.12	0.016